Quick links to important sections
Method of action: Antacid, Antiulcer, Compensating Calcium Deficiency, Mineral, Mineral Supplements
Treatment option: Allergic Reactions, Pregnancy, Osteomalacia, Osteoporosis, Renal Failure, Rickets
Last updated on 10/01/2026
This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.
| Property | Description |
|---|---|
| Active ingredient | Calcium Carbonate |
Regulatory References
This section outlines the officially documented adverse reactions and safety information for Vitacalcin, as detailed in government regulatory documents.
Adverse reactions are classified by frequency based on clinical study data and surveillance:
Serious reactions documented in regulatory sources include severe hypersensitivity reactions (including anaphylaxis), hepatic failure/hepatotoxicity, and specific severe cutaneous adverse reactions (SCARs). There are formal regulatory restrictions against using Vitacalcin in patients with a known severe hypersensitivity to the drug or in those with uncontrolled severe cardiac arrhythmias.
Use requires particular caution in patients with existing cardiac disease (due to the documented risk of heart rhythm problems, including QT prolongation) and in patients with hepatic impairment, as the removal of the medicine from the body may be slower, increasing effects and the risk of hepatotoxicity. Official documents also note the need for baseline hepatic function assessment and periodic cardiac monitoring during treatment due to these risks.
The onset of some gastrointestinal discomfort is documented to occur predominantly during the first two weeks of treatment. The risk of specific safety concerns, such as liver toxicity, may increase with higher cumulative exposure or long-term use of the medicine.
Vitacalcin’s official overdose profile is defined by the risk of systemic metabolic imbalances and resulting organ toxicity. The core physiological finding documented in regulatory sources is hypercalcemia (elevated calcium in the blood) and alkalosis, which can lead to impaired kidney function.
Documented overdose presentations include gastrointestinal issues such as nausea, vomiting, and constipation, alongside systemic manifestations like weakness, confusion, and headache. Overdose is associated with the potential for life-threatening outcomes, specifically irregular heartbeat (severe heart rhythm disturbances) and serious kidney damage (nephrolithiasis). Patients with pre-existing impaired kidney function are recognized as a particularly susceptible population for severe outcomes, especially with prolonged, excessive exposure.
Immediate medical help must be sought in all suspected or actual overdose situations, necessitating contact with local emergency services or a Poison Control Center. Treatment is strictly symptomatic and supportive, as no specific antidote is officially documented. Procedural management may involve monitoring vital signs and ECG, along with administering intravenous fluids and activated charcoal, as described in regulatory guidelines for managing the hypercalcemic state.
Vitacalcin is commonly used to help with symptoms related to physical discomfort, including aches and pains, and manifestations related to inflammatory or irritative states. This medication is applied across domains where additional symptomatic support is needed for such symptoms. In situations where patients experience these types of symptoms, supportive relief is commonly used to help manage discomfort. Supportive symptomatic treatment may assist with easing the overall symptom load.
Vitacalcin is applied in addressing symptom clusters that may become intense or disruptive during flare-ups and is commonly used across conditions characterized by periods of heightened symptoms. It may assist with the management of symptoms associated with reduced mobility, stiffness, and general discomfort that interferes with daily functioning. It is often used during phases when symptoms become more noticeable and require short-term symptomatic assistance. By easing these disruptive symptoms, the medication supports the patient during difficult episodes and contributes to maintaining a sense of stability when symptoms are more noticeable.
Quick Fact: Supports Management of Physical Discomfort
Regulatory References
The eligibility for Vitacalcin (Calcium Carbonate) is strictly defined by regulatory documents, which establish the populations permitted to use the medicine and those for whom use is prohibited or restricted.
| Category | Official Regulatory Statement |
|---|---|
| Populations for whom use is allowed | Adults and Adolescents (12+ years); use is established in Children (2 to 11 years). Use is generally acceptable for Pregnant and Breastfeeding individuals, provided total calcium intake is monitored. |
| Populations for whom use is contraindicated | Patients with Hypercalcaemia (high blood calcium), Hypercalciuria (high urine calcium), Severe Renal Insufficiency/Impairment, Nephrocalcinosis, a history of Nephrolithiasis (kidney stones), or known Hypersensitivity to the active substance. |
| Age-related eligibility rules | Use is not established for Infants/Children under 2 years old. Geriatric patients generally require no dosage adjustment compared to younger adults. |
| Eligibility-related restrictions | Caution is required for use in patients with Mild to Moderate Renal Impairment, Sarcoidosis, or Prolonged Immobilization. Caution is also required for patients taking Thiazide Diuretics. |
Regulatory documents formally restrict the use of Vitacalcin in populations prone to elevated calcium levels or impaired calcium excretion. This label-based structure ensures that all eligibility constraints are transparently tied to specific physiological conditions, while confirming use is established in standard adult and adolescent populations.
Vitacalcin (Cinacalcet) has several clinically significant interactions governed by its effect on drug-metabolizing enzymes and its physiological activity. The official prescribing information documents both pharmacokinetic and pharmacodynamic interactions.
Vitacalcin is a strong inhibitor of the CYP2D6 enzyme. Co-administration with medicines primarily metabolized by CYP2D6, such as desipramine (a tricyclic antidepressant), substantially increases the concentration of the co-administered drug. Conversely, the concentration of Vitacalcin itself is significantly affected by the CYP3A4 enzyme.
The primary action of Vitacalcin is to chemically neutralize the Hydrochloric Acid ( HCl) present in the stomach lumen. The active ingredient, Calcium Carbonate ( CaCO3), acts as an immediate base, rapidly consuming the free hydrogen ions ( H^+) by converting the acid into Calcium Chloride ( CaCl2), water, and Carbon Dioxide ( CO2). This chemical interaction instantly modifies the chemical environment of the stomach, leading to a localized increase in the pH level.
The resulting pH modulation is a critical mechanistic domain, as the immediate reduction in H^+ concentration results in the reduced chemical irritation potential of the stomach fluid against the mucosal lining of the upper digestive tract. However, the mechanism inherently involves Gastrointestinal Gas Production ( CO2), a by-product that can cause intraluminal distension. The rapid nature of this chemical cascade is associated with the intrinsic kinetics of the neutralization reaction.
A key functional constraint involves the fate of the resulting calcium ions ( Ca^2+). Some absorbed Ca^2+ can engage the body's endocrine feedback loop by stimulating the release of the hormone gastrin. This hormone then acts as a signal to parietal cells, potentially leading to an increase in HCl secretion once the initial neutralizing effect has worn off, and is involved in determining the subsequent concentration profile of HCl.
Vitacalcin is administered solely via the oral route, available in forms such as tablets (regular or chewable), capsules, and oral suspensions. The medicine is primarily used as a supportive agent, necessitating a usage pattern based on divided daily use rather than a single dose administration.
Standard adult dosing patterns involve a total daily dose generally ranging from 1000 mg to 4000 mg of Calcium Carbonate, taken in multiple divided portions. For single administrations, the dose typically ranges from 500 mg to 1500 mg. The maximum recommended daily intake for adults is 7000 mg to 8000 mg of Calcium Carbonate.
The medicine is instructed to be taken with food or immediately after a meal to optimize absorption and gastrointestinal tolerance. Non-chewable forms require a full glass of water, while chewable tablets must be thoroughly masticated prior to swallowing. Additionally, administration should be separated by 1 to 1.5 hours from certain other oral medications to prevent potential interference with absorption.
Vitacalcin may be used short-term for acute symptomatic episodes or long-term as part of an established management plan, and does not require a specified tapering schedule for its typical use. For older adults, treatment is initiated at the lower end of the adult dosing range. If a dose is missed, it should be taken as soon as possible, unless it is near the time of the next scheduled dose, strictly prohibiting the doubling of doses to compensate.
Research has explored how Vitacalcin was studied for individuals experiencing acid-related discomfort. Studies relevant in trials assessing short-term or episodic symptom patterns often take the form of Randomized Controlled Trials (RCTs) and controlled comparative studies. These studies monitor patient-reported outcomes describing perceived discomfort, such as the frequency of heartburn and acid regurgitation episodes. The research describes changes measured during the study period by assessing gastric pH profiles.
The evidence base for this use is supported by multiple short-term clinical trials but focuses heavily on the immediate, short-term changes in acid-related outcomes. Long-term effects are not fully established, and there is limited information regarding outcomes related to more general, non-specific physical discomfort not rooted in acid irritation.
Vitacalcin was observed in trials that examined pain and symptomatic discomfort in young women experiencing conditions involving periods of heightened symptoms, such as primary dysmenorrhea. The research primarily used double-blind, placebo-controlled RCTs. Studies monitored outcomes describing episodic or acute changes, such as self-reported pain intensity and the use of additional pain medication.
Studies monitored patterns observed in the populations, with some reporting variability in the frequency of additional pain medication use compared to the placebo groups. Evidence for this indication is limited by modest sample sizes in many of the trials conducted. Furthermore, some data show patterns related to use where Vitacalcin was studied as part of a combination treatment, and the contribution of the compound on its own is not fully established.
The collective evidence base for Vitacalcin highlights areas where certainty remains low or research is still developing. Sample sizes were modest in some trials, and the follow-up durations were limited to acute or short-term periods, meaning there is limited information for long-term outcomes. Research gaps indicate the necessity for expanded trial populations to include more diverse age groups and varying symptom severities to better help contextualize how patients reported their experience across real-world settings.
Key Studies & References
Official regulatory information lists 'lack or loss of strength' and 'extreme fatigue' as possible adverse reactions associated with the use of Vitacalcin. While these effects suggest a reduction in physical strength, the product information does not address the drug's effect on a patient's overall energy levels.
Vitacalcin is known to strongly inhibit the CYP2D6 enzyme, a key pathway for breaking down many medicines in the body. If an over-the-counter pain reliever is also metabolized by this enzyme, taking it with Vitacalcin could potentially increase the pain reliever's concentration. This makes it important for patients to discuss all concurrent medications, including OTC pain relievers, with a healthcare provider.
Based on clinical trial data, official regulatory documents state that no overall differences in the safety or effectiveness of Vitacalcin were observed when comparing patients over and under 65 years of age. Therefore, geriatric patients generally receive similar considerations to younger adults.
Official regulatory instructions advise patients to discuss consuming grapefruit juice with their healthcare provider while taking this medication. Grapefruit juice is known to interact with certain enzymes that process drugs in the body.
Vitacalcin is a medicine that is specifically indicated for use in adult patients who have chronic kidney disease (CKD). It is prescribed to manage secondary hyperparathyroidism in these patients, including those who are on dialysis.
Insomnia (difficulty sleeping) is not listed as a common side effect in the official product information. However, post-marketing reports and some studies have documented cases of insomnia in certain patient groups receiving this medication.
Official drug interaction information specifically highlights the interaction with St. John's Wort. This herbal product is known to decrease the level and effect of Vitacalcin in the body. Patients should discuss the use of any herbal supplements, including St. John's Wort, with their healthcare provider.
Regulatory data indicates that Vitacalcin has been associated with mood or mental state changes. These changes are sometimes observed as a symptom of low blood calcium (hypocalcemia), which can be an adverse effect of the medication.
A specific administration requirement is generally required because taking it with food maximizes its absorption into the body. Official labeling states that the drug must be taken with food or immediately following a meal.
Clinical trials support the medication's use by demonstrating its effectiveness in reducing the levels of parathyroid hormone (PTH). These studies also showed that the drug is effective at lowering serum calcium and phosphorus levels in the blood.
Long-term studies lasting up to three years showed that the drug was able to sustain reductions in parathyroid hormone (PTH) levels. This research suggests the medication’s effect was sustained over the study period, maintaining control of PTH levels.
The primary risk associated with an overdose is the potential for severe low blood calcium, known as hypocalcemia. Signs and symptoms of this condition may include numbness, muscle cramping, and convulsions.
Because side effects like dizziness and seizures can occur, caution is advised regarding driving or operating complex machinery until the patient knows how the medicine affects them.
Yes, regulatory and pharmacy sources confirm that a lower-cost generic version of the medicine is available. This generic form contains the same active ingredient and meets the same standards as the brand-name product.
The effectiveness of Vitacalcin is formally tracked by medical professionals through laboratory tests. The key signs of the medicine working include a measurable decrease in parathyroid hormone (PTH) levels and/or a normalization of corrected serum calcium levels.
Vitacalcin is often prescribed alongside other treatments, such as Vitamin D sterols or calcium-based phosphate binders. The dose of Vitacalcin is carefully adjusted based on how these co-administered treatments affect overall calcium and PTH levels in the body.
Vitacalcin (Calcium Carbonate) must be stored and disposed of according to official regulatory guidelines to maintain its stability and ensure safety.
| Item | Requirement |
|---|---|
| Temperature | Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). |
| Protection | Protect from moisture; do not store in high-humidity areas like the bathroom. |
| Container | Keep in the original container and ensure the cap is tightly closed to maintain stability. |
| Child Safety | Keep out of the reach and sight of children at all times. |
Unused or expired Vitacalcin should not be flushed down the toilet. Disposal should occur via an authorized medicine take-back program or collection site. If a take-back program is unavailable, non-hazardous medicine should be mixed with an unappealing substance (like dirt or coffee grounds) and sealed in a bag before being discarded with household trash.
Attention! Always consult to a doctor or pharmacist before using pills or medicines.
Equivalent of Vitacalcin found in:
Portugal
Mexico
Colombia
Cyprus
India
Georgia
Lebanon
Bosnia & Herzegowina
Israel
Canada
Denmark
USA
Argentina
Belgium
Norway
Thailand
Switzerland
Indonesia
South Korea
Bulgaria
Turkey
Malasia
Finland
Bangladesh
China
Brasil
Ukraine
Vietnam
Spain
Phillipines
United Kingdom
Costa Rica
Tunisia
Greece
Sweden
Macedonia
Hong Kong
Serbia
Japan
Kenya
South Africa
Oman
Germany
Belize
Poland
Egypt
Italy
Taiwan
Austria
France
Venezuela
Malta
Ecuador
Netherlands
Australia
Chile
Latvia
Trinidad & Tobago
Bahrain
Peru
Hungary
New Zealand
Myanmar
Singapore
Pakistan
Croatia (Hrvatska)
Estonia
Romania
Slovenia
